SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer strengthens on completing merger with Wyeth

03 Dec 2014 Evaluate

Pfizer is currently trading at Rs. 1848.60, up by 32.10 points or 1.77% from its previous closing of Rs. 1816.50 on the BSE.

The scrip opened at Rs. 1833.60 and has touched a high and low of Rs. 1858.00 and Rs. 1824.70 respectively. So far 2116 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1840.00 on 02-Dec-2014 and a 52 week low of Rs. 1020.00 on 04-Feb-2014.

Last one week high and low of the scrip stood at Rs. 1840.00 and Rs. 1668.95 respectively. The current market cap of the company is Rs. 5527.98 crore.

The promoters holding in the company stood at 70.75 % while Institutions and Non-Institutions held 8.68 % and 20.57 % respectively.

Drug major Pfizer announced completion of the merger with pharmaceutical company, Wyeth. The merger places Pfizer among the top ten drug companies in India by market share. As a result of the merger with Wyeth, Pfizer now has a significantly stronger portfolio of offerings across a wider therapeutic universe.

Pfizer Inc, USA, through its subsidiaries holds the majority stake in both companies and will continue to remain the majority shareholder with around 63.9 per cent holding in Pfizer post-merger. 

The company has debuted offering in vaccines segment and has planned to build a robust presence in areas of women's health with best known brands in Oral contraception and folic acid supplements. Pfizer reported a standalone loss of Rs 11.83 crore for the second quarter of current fiscal as compared to net profit of Rs 69.45 crore for same quarter of previous fiscal.

Pfizer Share Price

4794.05 -17.00 (-0.35%)
11-May-2026 09:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.45
Dr. Reddys Lab 1275.00
Cipla 1333.20
Zydus Lifesciences 932.75
Lupin 2237.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×